Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report released on Saturday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of NYSE BTX opened at $2.15 on Friday. The company has a market capitalization of $126.48 million, a PE ratio of -0.95 and a beta of 4.61. The stock’s 50 day moving average price is $2.18 and its 200-day moving average price is $1.81. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10.

Institutional Trading of Brooklyn ImmunoTherapeutics

A hedge fund recently raised its stake in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC increased its stake in Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,459,626 shares of the company’s stock after purchasing an additional 243,826 shares during the quarter. Renaissance Technologies LLC owned approximately 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.00% of the company’s stock.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.